Healthcare Industry News:  lumbar interbody fusion 

Devices Neurosurgery Orthopaedic

 News Release - August 27, 2013

Interventional Spine(R), Inc. Announces Issuance of Another Broad Patent Covering the Company's Opticage(TM) Expandable Fusion Cage and PerX360 System(TM) Percutaneous Fusion Procedure

IRVINE, Calif., Aug. 27, 2013 -- (Healthcare Sales & Marketing Network) -- Interventional Spine®, Inc. today announced that they have received further patent protection for their Opticage™ expandable fusion cage and PerX360 System™ procedure. The Company believes that PerX360 is a revolutionary new approach to minimally invasive lumbar interbody fusion.

The PerX360 System™ is a combination of Interventional Spine's state-of-the-art products, including the Opticage™ expandable interbody fusion device, the Optiport percutaneous tissue dilation instrument, and the BONE-LOK® transfacet-pedicular compression device. When used together, a complete 360 fusion can be performed through two incisions that are less than 12mm each, without the need to reposition the patient during surgery.

The Opticage™ is infinitely adjustable within its working range of 9mm to 14mm. The Optiport, which is designed to navigate safely past the exiting nerve roots, also has the ability to perform a foraminoplasty increasing the size of the vertebral foramen while protecting the spinal nerve root during the procedure.

Interventional Spine® has concentrated its efforts on proving the clinical utility of these proprietary technologies, with only limited sales effort. To date, there have been more than 540 implants of the Opticage™ and PerX360 System™ worldwide, with exceptional clinical results. The Company has trained a number of the top minimally invasive spine surgeons from the United States and around the world, including: Spain, Germany, Italy, U.K., Mexico, Chile, the Dominican Republic and Brazil.

Mr. Chris Warren, Vice President of Research and Development at Interventional Spine® commented: "This patent further solidifies the intellectual property of the innovative PerX360 procedure and the instrumentation used to perform it. In receiving these broad, protected claims, Interventional Spine® is uniquely positioned to lead innovation in what may be the next big spinal fusion procedure, and what many consider to be the holy grail of minimally invasive spine surgery. By providing this technology to spine surgeons, we feel it will ultimately benefit their patients by considerably improving both short-term and long-term outcomes, in addition to decreasing the length of hospital stays and decreasing post-operative surgical pain."

Mr. Walter A. Cuevas, Chief Executive Officer at Interventional Spine® also commented: "The issuance of this patent firmly positions Interventional Spine® as the leader in providing the least invasive surgical options to spine surgeons and their patients. It has been made possible only by the substantial effort and determination of our engineering team in collaboration with some of the top minimally invasive spine surgeons in the world. We continue to file additional patent applications further expanding the intellectual property claims for these technologies."

Interventional Spine®, Inc. is a privately held company based in Irvine, California, that designs, develops and markets patented implantable devices for the spine that can be deployed via percutaneous techniques. Supported by the Company's unique product introduction systems, Interventional Spine's products provide benefits to patients, surgeons and hospitals alike. The PerX360 System™ joins the current product offerings; the PERPOS® PLS System, the PERPOS® Percutaneous Cervical System, and the PDS System™.

More information on the Company and its products can be found at:

Source: Interventional Spine

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.